Journal of Diabetes and Clinical Research
Department of Medicine
Hofstra Northwell School of Medicine
Dimiter Avtanski is a Director of the Endocrine Research Laboratory at Friedman Diabetes Institute of Lenox Hill Hospital in New York City, Associate Professor of Medicine at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Hempstead, New York, and Assistant Professor at the Institute of Bioelectronic Medicine at Feinstein Institutes for Medical Research in Manhasset, New York. Dr. Avtanski received his M.Sc. degree in Biology and Chemistry from Sofia University in Bulgaria and his Ph.D. degree from the Bulgarian Academy of Sciences in collaboration with Beth Israel Medical Center at Albert Einstein College of Medicine in New York City. Dr. Avtanski specialized at Leipzig University, Germany and completed seven years of post-doctoral fellowships at the Johns Hopkins University School of Medicine in Baltimore, Maryland. His main research focuses on the connection between obesity, diabetes, carcinogenesis, and steroidogenesis. Dr. Avtanski serves as Associate Editor for the journals Molecular Medicine and BMC Endocrine Disorders, holds Guest Editor positions at the Journal of Visualized Experiments (JoVE) and other journals, and is an Editorial Board Member of several journals. He is an active reviewer for many peer reviewed journals, book chapters, conferences, and companies, for which he received multiple recognitions. Dr. Avtanski is a research mentor of rotating fellows from Lenox Hill Hospital, Hofstra University and Feinstein Institutes for Medical Research.
My expertise is in the areas of Endocrinology and Oncology. Our laboratory investigates the endocrine role of the adipose tissue and the molecular mechanisms of insulin resistance and breast cancer.
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.